Home > Immunology Assays > Tumour Cell Killing

---

Immune cell-mediated tumour cell killing

Immune cell-mediated killing of tumour cells is an important mode of action for several drugs. Celentyx provides assays using human primary immune cells, including purified CD8 T cells, γδ T cells, NK cells and monocytes/macrophages, that can be used for quantifying drug potency and efficacy. These assays can be performed using imaging or flow cytometry platforms. Also see the dedicated T cell activation, NK cell and monocyte/macrophage pages.

Assays may be suitable for evaluating Bispecific-T cell engagers (BiTEs), CAR-T cells and TCR-T, and modulators of 4-1BB, CD3, CD27, CD28, CD40, CD40L, CD70, CD80, CD86, CTLA-4, Fas, FasL, JAK1, JAK2, JAK3, ICOS, ICOSL, IL-2R, IL-9R, IL-21R, LAG-3 OX40, OX40L, PD-1, PDL-1, PDL-2, STAT1, STAT3, STAT5, TIGIT, TIM-3, and others​

Further Immunology Assays
Antigen-specific Assays
B Cells
Fibroblasts
Haemolysis Testing
​Human Microglia
​Macrophages/Monocytes
​Neutrophils/Granulocytes
​NK Cells
​Phagocytosis Assays
Regulatory T Cells
Spheroid Killing Assay​s​
​Suppression Assays​​
T Cell Activation Assays
​T Cell Exhaustion Assays
TIL and dissociated tumour cell assays​

Killing of tumour cells by CD8 T cells evoked by a bispecific T cell engager; Imaging

Specific tumour cell killing was monitored over time by high-throughput confocal microscopy.

Killing of tumour cells by NK cells by monoclonal antibody; Flow cytometry

Tumour cells were cultured with NK cells either at rest (Tumor cells + NK cells) or following pre-treatment with increasing concentrations of a test therapeutic.

Antibody-dependent enhancement of tumour cell phagocytosis

Phagocytosis of patient CLL cells by human monocyte-derived macrophages. Rituximab enhancement of CLL cell capture exhibited a ‘bell-shaped’ concentration-response emphasizing the importance of evaluating multiple concentrations.